US Patent Issued to The University of Chicago, Dana-Farber Cancer Institute on July 1 for "Compositions and methods for inhibition of FOXP3" (Illinois, Massachusetts Inventors)

ALEXANDRIA, Va., July 3 -- United States Patent no. 12,344,643, issued on July 1, was assigned to The University of Chicago (Chicago) and Dana-Farber Cancer Institute Inc. (Boston).

"Compositions and methods for inhibition of FOXP3" was invented by James LaBelle (Chicago), Rachel Eclov (Chicago), Gregory Bird (Boston) and Loren D. Walensky (Boston).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are peptide-based therapeutics that target FOXP3 and methods of use thereof to decrease the immuno-suppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammato...